EAVI2020

Introduction

HIV-1 is responsible for a global pandemic of almost 37 million people, and continues to spread at a rate over 2 million new infections/year. Developing safe, effective and affordable vaccines that can prevent HIV infection in uninfected people is the best hope for controlling and ultimately ending the HIV epidemic. Developing a therapeutic vaccine could also be beneficial for people living with HIV by helping slow the progression of the disease and prevent or delay the onset of AIDS.

Although researchers have been working on developing a vaccine for 30 years, we do not have a vaccine capable of protecting from HIV-1 infection or impacting on disease progression. However, recent advances are helping to speed up their quest. Scientists have isolated antibodies that are able to block HIV infection in preclinical models, and there have been new developments in using synthetic biology to design better vaccines. On the other hand, there are disappointing results of recent clinical trials point to bottlenecks in identifying viable candidate vaccines, which if unaddressed will continue to present significant risks of failure at relatively late stages of the development process. The European AIDS Vaccine Initiative (EAVI2020) has the challenge of shifting this ‘risk curve’ in order to better select successful vaccine candidates (and discard those with a higher risk of failure) at an earlier stage of the vaccine development process.

EAVI2020 will provide a platform for the discovery and selection of several new, diverse and novel preventive and/or therapeutic vaccine candidates for HIV/AIDS. Emphasis will be placed on early rapid, iterative, small Experimental medicine (EM) human vaccine studies to select and refine the best immunogens, adjuvants, vectors, homologous and heterologous prime–boost schedules, and determine the impact of host factors such as gender and genetics. Animal models will be used to complement human studies, and to select novel immunization technologies to be advanced to the clinic. To shift the “risk curve” in product development we will develop innovative risk prediction methods, specifically designed to reduce the risk associated with late stage vaccine failure, increasing the chance of discovery of an effective vaccine.

EAVI2020 (www.eavi2020.eu) has been funded with an EU-grant under the health program of Horizon 2020 for research and innovation with almost 23 million euros, and brings together some of the most competitive research groups in vaccine discovery from European public institutions and biotechs from Europe, Australia, Canada and the USA, providing a pool of international expertise at the highest level.

The Consortium

The EAVI2020 consortium is led by Imperial College London and brings together 23 partners, including some of the most competitive research groups in vaccine discovery from European public institutions and biotechs from 9 EU countries together with top Australian and Canadian groups and US collaborators:

1. Imperial College of Science Technology and Medicine. United Kingdom
2. The Chancellor, Masters and Scholars of the University of Oxford (UOXF). United Kingdom
3. Institut National de la Sante et de la Recherche Medicale (INSERM). France
4. Fundació Privada Institut de Recerca de la Sida (IrsiCaixa). Spain
5. Istituto Superiore di Sanita (ISS). Italy
6. Polymun Scientific Immunbiologische Forschung Gmbh. Austria
7. Fundacio Privada Clínic per a la Recerca Biomèdica (FCRB). Spain
8. Academisch Medisch Centrum bij de Universiteit van Amsterdam (AMC). Netherlands
9. Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA). France
10. Ospedale San Raffaele (OSR). Italy
11. Universite Joseph Fourier Grenoble 1 (UJF). France
12. King's College London (KCL). United Kingdom
13. Karolinska Institutet (KI). Sweden
14. Universitatsklinikum Erlangen (UKER). Germany
15. The University of Western Ontario (UWO). Canada
16. Nemzeti Elelmiszerlancbiztonsagi Hivatal (NFCSO –DVMP). Hungary
17. Ludwig Boltzmann Gesellschaft GmbH (LBG). Austria
18. Biontech RNA Pharmaceuticals GmbH (BioNTech RNA). Germany
19. Instituto de Salud Carlos III (ISCIII). Spain
20. Stichting International AIDS Vaccine Initiative the Netherlands (Stichting IAVI). Netherlands
21. University of Melbourne (UOM). Australia
22. University of New South Wales (UNSW). Australia
23. Genome Research Limited (GRL). United Kingdom

Objectives

The project has the following objectives:

  • Establishment of a platform for the discovery and selection of several new diverse and novel preventive or therapeutic vaccine candidates for HIV/AIDS, and their pre-clinical and early clinical testing.
  • Improvement of the process of early selection of candidates. Proposals should therefore pool expertise in the areas of “in vitro” and “in silico” testing, predictive animal models, predictive correlates of protection, phase 0 trials, first in man trials and innovative risk prediction methods, taking into account sex-specific differences. As a result, a reduction in the cost associated with late stage preventive or therapeutic vaccine failure is expected, increasing the number of other candidates which can be tested with the same resources, thus increasing the chance of discovery of an effective vaccine.
  • Development of novel candidate vaccines that can be taken through to human trials within five years.The successful proposal shall continue its vaccine development in the context of the European and Developing Countries Clinical Trials Partnership (EDCTP).

IP lab in EAVI2020

The role of the IP lab in the project will be to set up a central platform for the screening of neutralizing antibodies obtained through different immunogens in animal models and clinical trials. In addition, the researchers of the group will contribute designing new immunogens based on viruses transmitted during acute infection. This approach represents a new and original approach aim to define a new generation of immunogens to obtain a vaccine for HIV.

 

 

 

Go to top

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site